0001209191-18-033112.txt : 20180524
0001209191-18-033112.hdr.sgml : 20180524
20180524180615
ACCESSION NUMBER: 0001209191-18-033112
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20180522
FILED AS OF DATE: 20180524
DATE AS OF CHANGE: 20180524
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Ruff Shamim
CENTRAL INDEX KEY: 0001685986
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-14895
FILM NUMBER: 18859030
MAIL ADDRESS:
STREET 1: 215 FIRST STREET
STREET 2: SUITE 415
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Sarepta Therapeutics, Inc.
CENTRAL INDEX KEY: 0000873303
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 930797222
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 215 FIRST STREET
STREET 2: SUITE 415
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
BUSINESS PHONE: 617-274-4000
MAIL ADDRESS:
STREET 1: 215 FIRST STREET
STREET 2: SUITE 415
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
FORMER COMPANY:
FORMER CONFORMED NAME: Sarepta Therapuetics, Inc.
DATE OF NAME CHANGE: 20120712
FORMER COMPANY:
FORMER CONFORMED NAME: AVI BIOPHARMA INC
DATE OF NAME CHANGE: 19980930
FORMER COMPANY:
FORMER CONFORMED NAME: ANTIVIRALS INC
DATE OF NAME CHANGE: 19970123
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2018-05-22
0
0000873303
Sarepta Therapeutics, Inc.
SRPT
0001685986
Ruff Shamim
215 FIRST STREET
SUITE 415
CAMBRIDGE
MA
02142
0
1
0
0
SVP, Chief Regulatory Affairs
Common Stock
2018-05-22
4
M
0
4432
A
33241
D
Common Stock
2018-05-22
4
F
0
1305
89.22
D
31936
D
Restricted Stock Units
2018-05-22
4
M
0
4432
0.00
D
Common Stock
4432
0
D
Restricted stock units convert into common stock on a one-for-one basis.
Shares were withheld by the Company to satisfy tax withholding obligations related to a vesting of restricted stock units granted on March 10, 2017.
On March 10, 2017, the reporting person was granted restricted stock units that vest based on the Company's satisfaction of certain performance criteria. The first performance criterion was met on August 3, 2017, resulting in vesting of 50% of such restricted stock units, and the second performance criterion was met on May 22, 2018, resulting in vesting of 25% of such restricted stock units.
/s/ David Tyronne Howton, as Attorney-in-Fact for Shamim Ruff
2018-05-24